Cadila Healthcare stock downgraded

BofA-Merrill has downgraded Cadila Healthcare stock to 'underperform' from 'buy'.

Bank Of America-Merrill Lynch has downgraded Cadila Healthcare stock to ‘underperform’ from ‘buy’ and has cut target price to 900 rupees from 975 rupees citing sluggish sales growth in domestic,U.S. markets.

The company on Tuesday reported a mere 2.34 percent rise in April-June stand-alone net sales to 5.67 billion rupees . Lower sales growth momentum and USFDA Warning letter (injectibles facility) would pose near term overhang and limit upside potential,the Wall Street bank said in a note. Lower-than-expected impact on volumes due to price increase in consumer wellness business may also provide upside risk,it added.

At 9.50 a.m. shares were down 6.78 percent at 887.45 rupees.

Company INFO

More on Cadila Healthcare

Stocks

More on Cadila Healthcare

Cracks in BJP-AIADMK alliance again as Delhi ‘hand’ seen in bids to rock EPS

Political Pulse46 min ago

The AIADMK-BJP alliance is under pressure as the AIADMK accuses BJP of meddling in EPS's leadership. Calls for leaving NDA are increasing and OPS may form a new party. BJP's efforts to gain control in Tamil Nadu are being resisted by AIADMK leaders. Despite challenges, EPS maintains a strong grip on the party. BJP's attempts to unite AIADMK have failed, potentially bolstering EPS's leadership.

View all shorts

Live Blog